Rapid control of severe ectopic Cushing's syndrome by oral osilodrostat monotherapy

Eur J Endocrinol. 2021 May;184(5):L13-L15. doi: 10.1530/EJE-21-0147.

Authors

Laura Bessiène^{1

2}, Fidéline Bonnet^{3

4

2}, Florence Tenenbaum⁵, Mathieu Jozwiak^{6

2}, Anthony Corchia⁷, Jérôme Bertherat^{1

4

2}, Lionel Groussin^{1

4

2}

Affiliations

¹ Department of Endocrinology, Polyclinic of Saint Côme, Compiegne, France.
² Université de Paris, Paris, France.
³ Department of Hormonology, Polyclinic of Saint Côme, Compiegne, France.
⁴ INSERM Unité 1016, CNRS UMR 8104, Institut Cochin, Paris, France.
⁵ Department of Nuclear Medicine, Polyclinic of Saint Côme, Compiegne, France.
⁶ Medical ICU, APHP, Cochin Hospital, Paris, France.
⁷ Department of Nephrology, Polyclinic of Saint Côme, Compiegne, France.

PMID: 33667191
DOI: 10.1530/EJE-21-0147

No abstract available

Publication types

Case Reports
Letter

MeSH terms

ACTH Syndrome, Ectopic / blood
ACTH Syndrome, Ectopic / drug therapy*
Cushing Syndrome / blood
Cushing Syndrome / drug therapy*
Cytochrome P-450 Enzyme Inhibitors
Female
Humans
Hydrocortisone / blood
Imidazoles / administration & dosage*
Intensive Care Units
Middle Aged
Pyridines / administration & dosage*

Substances

Cytochrome P-450 Enzyme Inhibitors
Imidazoles
Pyridines
Osilodrostat
Hydrocortisone